Pancreatic cancer is an extremely lethal malignancy. On average, patients who are diagnosed with pancreatic cancer succumb to the disease within 6 months. Research is the only way to defeat pancreatic cancer. My lab is making progress toward finding a cure by detecting the disease earlier and designing novel therapeutic approaches.
David Tuveson’s laboratory uses murine and human models of pancreatic cancer to explore the fundamental biology of malignancy and thereby identify new diagnostic and treatment strategies. The lab’s approaches run the gamut from designing new model systems of disease to developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings. The lab’s studies make use of organoid cultures—three-dimensional cultures of normal or cancerous epithelia—as ex vivo models to probe cancer biology. Current projects in the lab explore changes in redox metabolism associated with pancreatic cancer tumorigenesis, dissect signaling by the Ras oncogene, discover new biomarkers of early pancreas cancer, and identify mechanisms of cross-talk between pancreatic cancer cells and the tumor stroma. Novel treatment approaches suggested by these studies are then tested by performing therapeutic experiments in mouse models. To dissect molecular changes associated with pancreatic tumorigenesis, the Tuveson lab has generated a large collection of human patient-derived organoid models. By measuring the therapeutic sensitivities of patient-derived organoids, the lab is working to identify novel strategies to treat patients as well as markers of therapeutic response. The Tuveson Laboratory maintains strong links to clinical research, and the ultimate goal is confirmation of preclinical findings in early-phase trials. Collectively, the lab’s bench-to-bedside approach is codified as the “Cancer Therapeutics Initiative,” and this initiative will provide these same approaches to the entire CSHL cancer community.
Dr. Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and the Chief Scientist for the Lustgarten Foundation.
Tuveson and Wigler elected AACR Academy Fellows
May 12, 2020
CSHL Cancer Center Director David Tuveson and Professor Michael Wigler were chosen as 2020 Fellows of the AACR Academy.
David Tuveson named President-Elect of AACR
April 21, 2020
CSHL Cancer Center Director David Tuveson has been elected President-Elect of the American Association for Cancer Research.
CSHL Cancer Center joins the AACI
January 10, 2020
The CSHL Cancer Center becomes the 100th member of the Association of American Cancer Institutes.
CSHL investigators rank among world’s most highly cited
December 11, 2019
Seven researchers affiliated with CSHL are among the scientists producing the top 1 percent of the most highly-cited research in the world.
CSHL wins TD Ready Challenge grant for organoid facility
December 3, 2019
CSHL is one of the recipients of the TD Ready Challenge grant to help support the upcoming organoid facility.
Learning about organoids at the CSHL Open House
October 17, 2019
Research Investigator Lindsey Baker, Ph.D., co-developed the organoid system for pancreatic cancer. In this video, she explains how it works.
Overcoming resistance in pancreatic cancer
September 9, 2019
Controlling pancreatic tumor proliferation by targeting malignancy-specific resistance pathways in response to AKT and MAPK blockade.
Of mice and model organisms
July 31, 2019
An in-depth look at how veterinarians at CSHL help take care of the various organisms that help researchers answer fundamental biological questions.
Cancer cell’s “self eating” tactic may be its weakness
July 1, 2019
Pancreatic cancer cells are eating their own mitochondria to survive and spread. New research reveals how, hinting at a possible new drug target.
Sugars that coat proteins are a possible drug target for pancreatitis
June 20, 2019
CA19-9, a complex sugar structure coating proteins, represents a possible drug target for treatment of pancreatitis and prevention of pancreatic cancer.